SCHEMBL523254

SCHEMBL523254

O=C(O)c1nc2ccc(Cl)cc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 2/20 0.66
HRH4 Q9H3N8 5/20 0.58
HRH3 Q9Y5N1 2/20 0.58
HSD17B10 Q99714 2/20 0.56
RAB9A P51151 1/20 0.56
POLB P06746 1/20 0.56
ALDH1A1 P00352 2/20 0.54
RHEB Q15382 1/20 0.54
HTR3E A5X5Y0 1/20 0.54
HTR3B O95264 1/20 0.54
HTR3A P46098 1/20 0.54
BACE1 P56817 1/20 0.54
HTR3D Q70Z44 1/20 0.54
HTR3C Q8WXA8 1/20 0.54
ALOX15 P16050 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
EGLN1 Q9GZT9 1/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
TP53 P04637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29527229 1.00 PIN1 (0.66) PIN1HRH4HRH3HSD17B10RAB9A
SCHEMBL3498398 0.87 CHEK2 (0.60) PIN1HRH4HRH3HSD17B10RAB9A
SCHEMBL523253 0.86 RHEB (0.54) PIN1HRH4HRH3RAB9APOLB
SCHEMBL11229268 0.86 HRH4 (0.58) PIN1HRH4HRH3HSD17B10RAB9A
SCHEMBL7152026 0.85 HTR3E (0.57) HRH4HRH3HSD17B10RAB9AALDH1A1
SCHEMBL4806542 0.81 PIN1 (0.68) PIN1POLBRHEBTDP1EGLN1
SCHEMBL13343598 0.80 KDM4E (0.57) PIN1HRH4HSD17B10POLBALDH1A1
SCHEMBL2243706 0.79 PIN1 (0.66) PIN1HRH4HRH3HSD17B10ALDH1A1
SCHEMBL21063893 0.79 PIN1 (0.66) PIN1HRH4RHEBTDP1EGLN1
SCHEMBL28429593 0.79 PIN1 (0.66) PIN1HRH4HRH3RHEBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12469929-B2 Separator, electrical apparatus containing such separator, and preparation method thereof CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) 2025-11-11 US claimed
EP-4397399-A2 MEMBRANES COMPRISING A LAYER OF METAL ORGANIC FRAMEWORK PARTICLES G2O Water Technologies Limited (GB) 2024-07-10 EP claimed
CN-108350034-B Antimicrobial polymyxin derived compounds 莫纳什大学 2022-03-11 CN claimed
EP-3774001-A1 MEMBRANES COMPRISING A LAYER OF METAL ORGANIC FRAMEWORK PARTICLES G2O Water Technologies Limited (GB) 2021-02-17 EP claimed
US-20210016232-A1 MEMBRANES COMPRISING A LAYER OF METAL ORGANIC FRAMEWORK PARTICLES EVOVE LTD (GB) 2021-01-21 US claimed
WO-2012175823-A1 NOVEL HYBRID ORGANIC/INORGANIC IM-22 SOLID, AND USE THEREOF IN THE SEPARATION OF MULTI-BRANCHED PARAFFINS FROM LINEAR AND SINGLE-BRANCHED PARAFFINS IFP Energies Nouvelles (FR) 2012-12-27 WO claimed
EP-2167077-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-31 EP claimed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 US claimed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 WO claimed
US-12629639-B2 Spacer for a spiral wound membrane EVOVE LTD (GB) 2026-05-19 US disclosed
EP-4660193-A1 INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2025-12-10 EP disclosed
US-12234398-B2 Metal organic framework (MOF) glass composite comprising metal halide perovskite THE UNIVERSITY OF QUEENSLAND (AU) 2025-02-25 US disclosed
US-20240376377-A1 A METAL ORGANIC FRAMEWORK (MOF) GLASS COMPOSITE COMPRISING METAL HALIDE PEROVSKITE THE UNIVERSITY OF QUEENSLAND (AU) 2024-11-14 US disclosed
WO-2024162746-A1 INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF 한국화학연구원 2024-08-08 WO disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed
EP-1051176-A4 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARM PROD INC (US) 2002-06-12 EP disclosed
CN-1291892-A Substituted oxoazaheterocyclyl factor Xa inhibitors AWENTIS PHARMACEUTICAL INC (US) 2001-04-18 CN disclosed
EP-1051176-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2000-11-15 EP disclosed
WO-2000032590-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-08 WO disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 PIN1 2950/4885HRH4 129/4885HRH3 203/4885
US-12629639-B2 Spacer for a spiral wound membrane AQP1, AQP3, AQP4 PIN1 3096/4885HRH4 3815/4885HRH3 4238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.